论文部分内容阅读
目的 探讨短期新辅助治疗(NHT)后前列腺癌组织学及癌细胞内聚集素蛋白表达的变化及其临床意义。方法 采用免疫组织化学方法,对未行雄激素阻断治疗的 26例前列腺癌患者前列腺癌根治术(RP)标本(26份,无NHT组 ), 19例行 3个月NHT患者NHT前穿刺活检标本及NHT后的RP标本(NHT组),行前列腺癌组织内聚集素蛋白表达水平的测定,观察NHT对癌组织中聚集素蛋白表达水平的影响。结果 聚集素主要存在于前列腺癌细胞的细胞浆中,部分存在于细胞外间质。NHT组NHT前癌组织中聚集素表达较弱,染色强度平均值为 1 .42±0 .51,NHT后表达较强,染色强度平均值为 2 .16±0. 60(t=7. 10,P<0. 01);NHT组NHT后聚集素表达高于无NHT组 (染色强度平均值为 1 .57±0. 70,t=2 91,P<0 .01)。结论 雄激素阻断治疗可使前列腺癌细胞内聚集素适应性上调,针对聚集素的辅助治疗可提高激素阻断治疗的效果。
Objective To investigate the histopathology of prostate cancer and the expression of aggrecan protein in cancer cells after short-term neoadjuvant therapy (NHT) and its clinical significance. Methods Twenty-six cases of prostate cancer radical mastectomy (26 cases with no NHT group) underwent androgen blockade without prostate cancer and 19 cases with NHT before 3 months were enrolled in this study. And NH specimens (NHT group). The expression of aggrecan protein in prostate cancer tissue was determined and the effect of NHT on the expression of aggrecan protein in cancer tissue was observed. Results Aggrecan mainly existed in the cytoplasm of prostate cancer cells and partially in the extracellular matrix. NHT group of NHT pre-cancerous tissue agglutinin expression is weak, the average staining intensity of 1.42 ± 0.51, NHT strong expression, the average staining intensity of 2.16 ± 0.60 (t = 7. 10 , P <0.01). The expression of NHT post-coagulation in NHT group was higher than that in the non-NHT group (average intensity of staining was 1.57 ± 0.70, t = 2 91, P <0.01). Conclusions Androgen blockade therapy can increase the adaptability of plasma agglutinin in prostate cancer cells. The adjuvant therapy with coagulation enhances the effect of hormone blockade therapy.